• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组化在膀胱原发性与继发性肠道腺癌鉴别诊断中的应用

Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.

作者信息

Raspollini Maria Rosaria, Nesi Gabriella, Baroni Gianna, Girardi Lucia Roberta, Taddei Gian Luigi

机构信息

Department of Human Pathology and Oncology, University of Florence, School of Medicine, Italy.

出版信息

Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):358-62. doi: 10.1097/01.pai.0000136552.44045.0f.

DOI:10.1097/01.pai.0000136552.44045.0f
PMID:16280666
Abstract

Distinguishing between primary adenocarcinomas and secondary colonic adenocarcinomas of the urinary bladder is often difficult because they appear morphologically similar but invariably require different treatment strategies. The aim of the study was to define the utility of a limited immunohistochemical panel consisting of CDX-2, cytokeratins 7 (CK7) and 20 (CK20), and carcinoembryonic antigen (CEA) in differentiating primary from secondary bladder adenocarcinomas. Formalin-fixed, paraffin-embedded tissues from 8 primary bladder adenocarcinomas and 23 colorectal adenocarcinomas involving the bladder were included in the study. Statistical analysis was performed using the Fisher exact test. The majority (87.5%) of primary bladder adenocarcinomas were CDX-2 negative, and only one case of primary bladder adenocarcinoma was positive, while CDX-2 was strongly expressed in the nucleus of all cases of secondary (colonic) bladder tumor (P < 0.0005). Five cases (62.5%) of primary bladder adenocarcinoma and one case (4.3%) of secondary bladder tumor showed positive staining for CK7 (P = 0.002), whereas CK20 showed positive staining in five cases (62.5%) of primary bladder adenocarcinoma and in all the secondary bladder tumors (P = 0.012). All 23 secondary bladder tumors and 7 primary bladder adenocarcinomas (87.5%) expressed CEA (P = 0.25). These data demonstrate that a restricted immunohistochemical panel consisting of CDX-2, CK7, CK20, and CEA may be of use in differentiating primary bladder adenocarcinoma from secondary adenocarcinoma of colorectal origin.

摘要

区分原发性膀胱腺癌和继发性膀胱结肠腺癌往往很困难,因为它们在形态上相似,但治疗策略却截然不同。本研究的目的是确定由尾型同源盒转录因子2(CDX-2)、细胞角蛋白7(CK7)和20(CK20)以及癌胚抗原(CEA)组成的有限免疫组化组合在鉴别原发性和继发性膀胱腺癌中的作用。本研究纳入了8例原发性膀胱腺癌和23例累及膀胱的结直肠癌的福尔马林固定石蜡包埋组织。采用Fisher精确检验进行统计分析。大多数原发性膀胱腺癌(87.5%)CDX-2阴性,仅1例原发性膀胱腺癌阳性,而CDX-2在所有继发性(结肠)膀胱肿瘤病例的细胞核中均强烈表达(P<0.0005)。5例原发性膀胱腺癌(62.5%)和1例继发性膀胱肿瘤(4.3%)CK7染色阳性(P=0.002),而CK20在5例原发性膀胱腺癌(62.5%)和所有继发性膀胱肿瘤中染色阳性(P=0.012)。所有23例继发性膀胱肿瘤和7例原发性膀胱腺癌(87.5%)表达CEA(P=0.25)。这些数据表明,由CDX-2、CK7、CK20和CEA组成的有限免疫组化组合可能有助于鉴别原发性膀胱腺癌和结直肠来源的继发性腺癌。

相似文献

1
Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.免疫组化在膀胱原发性与继发性肠道腺癌鉴别诊断中的应用
Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):358-62. doi: 10.1097/01.pai.0000136552.44045.0f.
2
Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.细胞角蛋白7、细胞角蛋白20、尾型同源盒转录因子-2和绒毛蛋白在肠型鼻窦腺癌中的表达模式
J Clin Pathol. 2004 Sep;57(9):932-7. doi: 10.1136/jcp.2004.016964.
3
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.膀胱原发性腺癌与继发性结直肠癌的免疫组织化学鉴别
Am J Surg Pathol. 2001 Nov;25(11):1380-7. doi: 10.1097/00000478-200111000-00005.
4
Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.原位肠型宫颈腺癌和腺癌表现出部分肠道免疫表型,伴有CDX2的一致性表达。
Int J Gynecol Pathol. 2008 Jan;27(1):92-100. doi: 10.1097/pgp.0b013e31815698e7.
5
Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel.原发性宫颈腺癌伴肠化生及结肠癌转移至宫颈:一项使用Cdx-2及有限免疫组化检测板的研究
Arch Pathol Lab Med. 2003 Dec;127(12):1586-90. doi: 10.5858/2003-127-1586-PCAWID.
6
Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.甲状腺转录因子1、PE-10以及细胞角蛋白7和20在细针穿刺活检标本中鉴别原发性肺癌与转移瘤中的应用。
Cancer. 2001 Oct 25;93(5):330-6. doi: 10.1002/cncr.9048.
7
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.一组抗体用于鉴定表现为膀胱癌的腺癌原发起源的价值。
Histopathology. 1998 Jan;32(1):20-7. doi: 10.1046/j.1365-2559.1998.00328.x.
8
The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.CDX2 和细胞角蛋白 7、20 表达在鉴别结直肠腺癌与肠外胃肠道腺癌中的价值:细胞角蛋白 7-/20+表型比 CDX2 抗体更具特异性。
Diagn Pathol. 2012 Jan 23;7:9. doi: 10.1186/1746-1596-7-9.
9
Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.卵巢原发性腺癌与结肠和乳腺来源的卵巢转移癌之间的免疫组织化学鉴别。统计学方法与直观方法的比较。
J Clin Pathol. 1999 Apr;52(4):283-90. doi: 10.1136/jcp.52.4.283.
10
[Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].甲状腺转录因子-1、表面活性蛋白-B、细胞角蛋白7和细胞角蛋白20在鉴别原发性与转移性肺腺癌中的应用
Zhonghua Yi Xue Za Zhi. 2003 Aug 10;83(15):1350-2.

引用本文的文献

1
Unexpected Metastasis of Primary Colonic Adenocarcinoma: A Case Report and Literature Review.原发性结肠腺癌的意外转移:一例报告及文献综述
Cureus. 2024 Jun 27;16(6):e63299. doi: 10.7759/cureus.63299. eCollection 2024 Jun.
2
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.脐尿管癌:来自法国泌尿生殖肿瘤组的一项大型回顾性多中心研究。
Front Oncol. 2023 Jan 19;13:1110003. doi: 10.3389/fonc.2023.1110003. eCollection 2023.
3
Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.
尿路上皮癌:不同分化和形态亚型。
Surg Pathol Clin. 2022 Dec;15(4):641-659. doi: 10.1016/j.path.2022.07.003. Epub 2022 Oct 13.
4
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.脐尿管癌和膀胱腺癌的生物标志物:综述补充自有数据。
Dis Markers. 2018 Mar 12;2018:7308168. doi: 10.1155/2018/7308168. eCollection 2018.
5
Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature.肾盂、输尿管及膀胱原发性腺癌:一例报告并文献复习
Oncol Lett. 2016 Mar;11(3):1811-1814. doi: 10.3892/ol.2016.4151. Epub 2016 Jan 26.
6
Adenocarcinoma of the urinary bladder.膀胱腺癌
Am J Clin Exp Urol. 2015 Aug 8;3(2):51-63. eCollection 2015.
7
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge.原发性膀胱腺癌与转移性结直肠腺癌:持续存在的诊断挑战。
Diagn Pathol. 2012 Nov 2;7:151. doi: 10.1186/1746-1596-7-151.
8
Immunohistochemical features of the gastrointestinal tract tumors.胃肠道肿瘤的免疫组织化学特征。
J Gastrointest Oncol. 2012 Sep;3(3):262-84. doi: 10.3978/j.issn.2078-6891.2012.019.
9
Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.基于 NCBI Literature Survey 和 Human Protein Atlas 数据库的免疫组织化学分析对盆腔器官癌进行直肠癌鉴别。
Surg Today. 2012 Jun;42(6):515-25. doi: 10.1007/s00595-012-0167-z. Epub 2012 Mar 23.
10
Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.膀胱癌腺癌对 FOLFOX 加贝伐单抗的持续缓解。
Nat Rev Urol. 2011 May;8(5):282-5. doi: 10.1038/nrurol.2011.48. Epub 2011 Apr 12.